A pharmaceutical version of bremelanotide (branded as Vyleesi) has received FDA approval as a prescription medication for a specific indication. OSYRIS PT-141 is a research-grade compound and is NOT a pharmaceutical product. It is sold exclusively for in vitro and preclinical research.

PT-141 was derived from Melanotan II but has a different receptor selectivity profile. Melanotan II is a less selective melanocortin agonist that acts on MC1R through MC5R. PT-141 is more selective for MC3R and MC4R. PT-141 also has a cyclic structure that gives it different pharmacokinetic properties.

Melanocortin receptors are a family of five G-protein coupled receptors (MC1R through MC5R) found throughout the body. They are activated by melanocortin peptide hormones and are involved in pigmentation (MC1R), adrenal function (MC2R), energy balance and sexual function (MC3R, MC4R), and exocrine gland function (MC5R).

No. PDE5 inhibitors act peripherally on vascular smooth muscle through the nitric oxide/cGMP pathway. PT-141 acts centrally through melanocortin receptors in the CNS. These are fundamentally different mechanisms, which is why researchers study PT-141 as an alternative pharmacological approach.

C₅₀H₆₈N₁₄O₁₀, with a molecular weight of approximately 1025.2 g/mol.

Store lyophilized PT-141 at 2-8°C, protected from light. Once reconstituted, refrigerate and use within your research protocol's designated timeframe.

Every batch is independently tested using HPLC and LC-MS analysis. The Certificate of Analysis is downloadable on this page.

Currently, yes. PT-141 is the only compound in the Sexual & Hormonal Health category. Additional compounds (Kisspeptin, HCG, Oxytocin) are planned for future catalog expansion.

MC4R, one of PT-141's primary targets, plays a well-documented role in appetite regulation and energy homeostasis. Loss-of-function mutations in the MC4R gene are the most common single-gene cause of severe obesity in humans. Researchers use melanocortin agonists like PT-141 to study this receptor system.